Cell-embedded vascular graft for transplantation
Inventors
Zayed, Mohamed A. • Millman, Jeffrey R.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12678538-B2
Publication Date
2026-07-14
Expiration Date
Abstract
Disclosed herein is a transplantation graft for transplanting cells into a patient. In an aspect, the graft may include a first graft layer having a generally cylindrical configuration defining a lumen therethrough, a coating layer surrounding the first graft layer, and a plurality of cells or vectors implanted in either the first graft layer or the coating layer. Further disclosed herein is a method for transplanting cells into a patient and a method of treating a patient in need thereof. The transplantation graft may be implanted in the patient in an arteriovenous configuration and the coating layer protects the implanted cells from the patient's immune system. The plurality of cells in the transplantation graft may release a biologically active agent in response to a biological factor in blood flowing through the lumen of the transplantation graft.
Core Innovation
The invention provides a transplantation graft for transplanting cells into a patient, including a first graft layer having a generally cylindrical configuration that defines a lumen configured to receive a blood flow directly therethrough, with the first graft layer directly contacting the blood flow within the lumen. The graft further includes a non-alginate coating layer surrounding the first graft layer and is configured to be implanted in an arteriovenous configuration.
A plurality of implanted cells are encapsulated within a plurality of alginate microbeads embedded within either the first graft layer or the non-alginate coating layer. The non-alginate coating layer protects the implanted cells from the patient's immune system, while the disclosed configuration provides direct access to blood flow through the lumen.
The encapsulated implanted cells are configured to release a biologically active agent in response to a biological factor in blood flowing through the lumen of the transplantation graft. In particular contexts described in the document, the biological factor includes glucose and the biologically active agent includes insulin.
Claims Coverage
The partial document contains three independent claims centered on an arteriovenous cell-implantation platform with a generally cylindrical lumen, a non-alginate coating layer, and implanted cells encapsulated within alginate microbeads embedded in the graft layer and/or the coating; one claim further requires blood-factor-responsive release of a biologically active agent.
Arteriovenous cylindrical lumen graft with immune-protective non-alginate coating
A transplantation graft for transplanting cells into a patient, comprising a first graft layer having a generally cylindrical configuration defining a lumen configured to receive patient blood flow directly therethrough with direct contact, a non-alginate coating layer surrounding the first graft layer, and a plurality of implanted cells encapsulated within alginate microbeads imbedded within either the first graft layer or the non-alginate coating layer, wherein the transplantation graft is configured to be implanted in the patient in an arteriovenous configuration, and wherein the non-alginate coating layer protects the implanted cells from the patient's immune system.
Blood-factor-responsive release of biologically active agent from the graft
A method of treating a patient in need thereof comprising implanting a transplantation graft into the patient in an arteriovenous configuration, the transplantation graft including a first graft layer having a generally cylindrical configuration defining a lumen configured to receive patient blood flow therethrough with the first graft layer directly contacting the blood flow within the lumen, a non-alginate coating layer surrounding the first graft layer, and a plurality of implanted cells encapsulated within alginate microbeads imbedded within either the first graft layer or the non-alginate coating layer, wherein the non-alginate coating layer protects the implanted cells from the patient's immune system, wherein the plurality of implanted cells release a biologically active agent in response to a biological factor in blood flowing through the lumen of the transplantation graft.
The inventive features collectively define an arteriovenous transplantation graft with a generally cylindrical lumen, a surrounding non-alginate immune-protective coating layer, and implanted cells encapsulated in alginate microbeads embedded in the graft layer and/or coating; the treatment claim further requires release of a biologically active agent in response to a biological factor in blood flowing through the graft lumen.
Stated Advantages
Protecting the implanted cells from the patient's immune system.
Enabling release of a biologically active agent in response to a biological factor in blood flowing through the graft lumen.
Documented Applications
Transplanting cells into a patient using an arteriovenous transplantation graft.
Treating a patient in need thereof by implanting an arteriovenous transplantation graft that releases a biologically active agent in response to a biological factor in blood flowing through the graft lumen.
Interested in licensing this patent?